AstraZeneca’s Saphnelo (anifrolumab-fnia) was approved in the United States for the treatment of adult patients with moderate to severe systemic lupus erythematosus who are receiving standard therapy.
Bristol Myers Squibb’s experimental psoriasis drug deucravacitinib (BMS-986165) beat out Amgen’s Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial.
Researchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.
Progentec Diagnostics Inc. launched a novel blood test to determine the likelihood that a patient with systemic lupus erythematosus (commonly known as both SLE and lupus) will experience an immunologic disease flare during the coming 12 weeks.
Despite the success Gilead Sciences has experienced with the JAK inhibitor filgotinib in rheumatoid arthritis, the medication failed to hit the mark in mid-stage trials aimed at lupus and Sjogren’s syndrome.
AstraZeneca’s experimental drug to treat moderate-to-severe lupus met the main goal in a late-stage trial. During 2018, anifrolumab failed to meet the primary target in the final stage of another study.
IFM Therapeutics launched a second subsidiary in less than a year. The Boston-based company launched IFM Due, a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases such as NASH, lupus and Parkinson’s.
Cambridge, Mass.-based Biogen and Brussels, Belgium-based UCB’s Phase IIb trial of dapirolizumab pegol in lupus failed to hit the primary endpoint, however, the study did show some efficacy and met other secondary endpoints.
AstraZeneca’s anifrolumab failed to meet the experimental drug’s main target in a late-stage clinical study treating patients with moderate to severe lupus.
Eli Lilly and Co. said the company’s drug to treat the autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a larger study in 2018.
